help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Domagala, W.
Right arrow Articles by Osborn, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domagala, W.
Right arrow Articles by Osborn, M.

American Journal of Pathology, Vol 137, 1299-1304, Copyright © 1990 by American Society for Investigative Pathology


REGULAR ARTICLES

Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas

W Domagala, J Lasota, A Dukowicz, M Markiewski, G Striker, K Weber and M Osborn
Department of Tumor Pathology, Medical Academy, Szczecin, Poland.

Vimentin expression in tumors from 83 node-negative and 112 node- positive patients with infiltrative ductal not otherwise specified (NOS) breast carcinomas has been compared with 5-year survival. For node-negative, but not for node-positive patients, there was a significant inverse relation between vimentin expression and survival. Five-year survival of node-negative patients with vimentin-positive tumors was significantly worse compared with vimentin-negative tumors (P less than 0.0001). In the node-negative group, only 36% of patients with vimentin-positive tumors but 82% of patients with vimentin- negative tumors survived 5 years. Tumors of all eight node-negative patients with ductal NOS cancer who died in the first 27 months expressed vimentin. Multivariate analysis of the node-negative group showed a strong correlation of vimentin expression and overall survival, but weak and not significant correlation between histologic grade or size and overall survival at 5 years. Thus vimentin expression seems to be a strong indicator of poor prognosis in node-negative ductal NOS breast carcinomas.


This article has been cited by other articles:


Home page
Cancer Res.Home page
R. A. Whipple, E. M. Balzer, E. H. Cho, M. A. Matrone, J. R. Yoon, and S. S. Martin
Vimentin Filaments Support Extension of Tubulin-Based Microtentacles in Detached Breast Tumor Cells
Cancer Res., July 15, 2008; 68(14): 5678 - 5688.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S. M. Rodriguez-Pinilla, D. Sarrio, E. Honrado, G. Moreno-Bueno, D. Hardisson, F. Calero, J. Benitez, and J. Palacios
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas
J. Clin. Pathol., September 1, 2007; 60(9): 1006 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Willipinski-Stapelfeldt, S. Riethdorf, V. Assmann, U. Woelfle, T. Rau, G. Sauter, J. Heukeshoven, and K. Pantel
Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells
Clin. Cancer Res., November 15, 2005; 11(22): 8006 - 8014.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Galie, C. Sorrentino, M. Montani, L. Micossi, E. Di Carlo, T. D'Antuono, L. Calderan, P. Marzola, D. Benati, F. Merigo, et al.
Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells
Carcinogenesis, November 1, 2005; 26(11): 1868 - 1878.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Society for Investigative Pathology.